Jazz Pharmaceuticals (JAZZ) Other financing activities (2012 - 2026)

Jazz Pharmaceuticals' Other financing activities history runs 15 years deep, the most recent figure standing at $32.9 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 186.09% year-over-year to $32.9 million in Q1 2026; TTM through Mar 2026 was $129.3 million, a 308.38% increase from a year earlier, with the FY2025 full-year figure at $107.9 million, up 422.41% from the prior year.
• Other financing activities fell to $32.9 million in Q1 2026 per JAZZ's latest filing, from $85.2 million in the prior quarter.
• Across five years, Other financing activities topped out at $85.2 million in Q4 2025 and bottomed at $17000.0 in Q3 2024.
• The 5-year median for Other financing activities is $10.9 million (2024), against an average of $18.0 million.
• Across the five-year window, Other financing activities slumped 99.69% in 2024 and surged 4211.76% in 2025, its largest moves.
• Year by year, Other financing activities stood at $30.2 million in 2022, then sank by 70.64% to $8.9 million in 2023, then increased by 3.87% to $9.2 million in 2024, then soared by 826.34% to $85.2 million in 2025, then tumbled by 61.38% to $32.9 million in 2026.
• Per Business Quant, the three latest JAZZ Other financing activities figures stand at $32.9 million (Q1 2026), $85.2 million (Q4 2025), and $733000.0 (Q3 2025).